logo

English
                 

        An E-Mail came from one of my classmate's son who is a doctor appearing in the NBC interviews.
        A review of studies in the medical journal Lancet suggests the benefits of aspirin may outweigh the risks.
        Aspirin users have a 36 percent lower risk for having their cancers spread
        and those who take aspirin have a 38 percent lower chance of developing colorectal cancer.
        NBC’s Dr. Nancy Snyderman reports.


        http://www.msnbc.msn.com/id/3032619/vp/46801645#46801645

        The following article backs up the NBC reports.

 

The Lancet, Volume 377, Issue 9759, Pages 31 - 41, 1 January 2011

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

Prof Peter M Rothwell FMedSci, Prof F Gerald R Fowkes FRCPE b, Prof Jill FF Belch FRCP c, Hisao Ogawa MD d, Prof Charles P Warlow FMedSci e, Prof Tom W Meade FRS f

Summary

Background

Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer. Several lines of evidence suggest that aspirin might also reduce risk of other cancers, particularly of the gastrointestinal tract, but proof in man is lacking. We studied deaths due to cancer during and after randomised trials of daily aspirin versus control done originally for prevention of vascular events.

Methods

We used individual patient data from all randomised trials of daily aspirin versus no aspirin with mean duration of scheduled trial treatment of 4 years or longer to determine the effect of allocation to aspirin on risk of cancer death in relation to scheduled duration of trial treatment for gastrointestinal and non-gastrointestinal cancers. In three large UK trials, long-term post-trial follow-up of individual patients was obtained from death certificates and cancer registries.

Results

In eight eligible trials (25 570 patients, 674 cancer deaths), allocation to aspirin reduced death due to cancer (pooled odds ratio [OR] 0·79, 95% CI 0·68—0·92, p=0·003). On analysis of individual patient data, which were available from seven trials (23 535 patients, 657 cancer deaths), benefit was apparent only after 5 years' follow-up (all cancers, hazard ratio [HR] 0·66, 0·50—0·87; gastrointestinal cancers, 0·46, 0·27—0·77; both p=0·003). The 20-year risk of cancer death (1634 deaths in 12 659 patients in three trials) remained lower in the aspirin groups than in the control groups (all solid cancers, HR 0·80, 0·72—0·88, p<0·0001; gastrointestinal cancers, 0·65, 0·54—0·78, p<0·0001), and benefit increased (interaction p=0·01) with scheduled duration of trial treatment (≥7·5 years: all solid cancers, 0·69, 0·54—0·88, p=0·003; gastrointestinal cancers, 0·41, 0·26—0·66, p=0·0001). The latent period before an effect on deaths was about 5 years for oesophageal, pancreatic, brain, and lung cancer, but was more delayed for stomach, colorectal, and prostate cancer. For lung and oesophageal cancer, benefit was confined to adenocarcinomas, and the overall effect on 20-year risk of cancer death was greatest for adenocarcinomas (HR 0·66, 0·56—0·77, p<0·0001). Benefit was unrelated to aspirin dose (75 mg upwards), sex, or smoking, but increased with age—the absolute reduction in 20-year risk of cancer death reaching 7·08% (2·42—11·74) at age 65 years and older.

Interpretation

Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.

Funding

None.
No. Subject Date Author Last Update Views
Notice How to write your comments onto a webpage [2] 2016.07.06 운영자 2016.11.20 18194
Notice How to Upload Pictures in webpages 2016.07.06 운영자 2018.10.19 32376
Notice How to use Rich Text Editor [3] 2016.06.28 운영자 2018.10.19 5929
Notice How to Write a Webpage 2016.06.28 운영자 2020.12.23 43843
523 Golf In The Kingdom/ Michael Murphy [2] 2019.11.06 이한중*65 2019.11.09 71
522 [Medical] Seaweed Based Drug For Alzheimer's [4] 2019.11.04 이한중*65 2019.11.06 171
521 Questions Regarding Flu Shots Answered By CDC [1] 2019.11.06 이한중*65 2019.11.06 107
520 [Medical] Best Time To Take BP Meds [1] 2019.10.24 이한중*65 2019.10.24 79
519 [Medical] The Story of Childhood Statin Initiation [7] 2019.10.21 이한중*65 2019.10.23 84
518 [Medical] Aducanumab, A Winner for Alzheimer's? [1] 2019.10.22 이한중*65 2019.10.22 40
517 [Medical] Cequa, New Drug, For Dry Eye Diseae [2] 2019.10.20 이한중*65 2019.10.21 101
516 [Medical] PIP Approach For PAF Management [3] 2019.10.15 이한중*65 2019.10.18 12264
515 The First Slim Hope For Sensorineural Hearing Loss [1] 2019.10.13 이한중*65 2019.10.13 50
514 [Medical] Osteoarthritis and Exercise [1] 2019.09.15 이한중*65 2019.09.16 121
513 What An Incredible Story! [3] 2019.07.27 이한중*65 2019.07.27 30391
512 [Medical] Lack of Clinical Trial Data For Elderly [1] 2019.07.15 이한중*65 2019.07.17 80
511 [Medical]Principles & Techniques Of BP Measurement [1] 2019.06.14 이한중*65 2019.06.14 51
510 백롱민 분당서울대병원장; 얼굴기형무료수술 30년 [2] 2019.05.31 온기철*71 2019.05.31 81
509 [Medical] LATE, Dementia Affecting People Over 80 [2] 2019.05.24 이한중*65 2019.05.24 93
508 [Medical] Dementia vs Alzheimer's [3] 2019.04.25 이한중*65 2019.05.03 133
507 [Medical] Skipping Breakfast Increases CV Death Rate [2] 2019.04.24 이한중*65 2019.04.28 72
506 [Medical] Longevity Gene [2] 2019.04.23 이한중*65 2019.04.23 52
505 [Medical] Safety Comparison, Apixaban vs Rivaroxaban [1] 2019.03.24 이한중*65 2019.03.24 52
504 [Medical] Elderberry and URI [2] 2019.03.17 이한중*65 2019.03.17 129